Comparison of loss of response between anti-tumor necrosis factor alone and combined use with immunomodulators in patients with inflammatory bowel disease
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: Combination therapy with immunomodulators (IMMs) was proposed as a strategy to prevent the development of loss of response (LOR) to anti- tumor necrosis factor (TNF) for patients with inflammatory bowel disease (IBD). However, the effect is unclear in patients already exposed to IMMs. The aim of this study was to evaluate whether combination therapy with IMMs is superior to monotherapy for prevention of LOR to anti-TNF. Methods: This was a retrospective study of patients in Seoul National University Bundang Hospital with IBD between January 2009 and October 2018. LOR was defined as clinical deterioration after maintenance of anti-TNF for at least 6 months. We investigated the difference in incidence of LOR to anti-TNF between the monotherapy and combination groups. We additionally assessed factors affecting LOR development to anti-TNF. Results: A total of 116 patients with IBD were included in this study (monotherapy 61 patients; combination 55 patients). Overall, LOR to anti-TNF occurred in 31 patients during the follow-up period. The combination of an anti-TNF agent and IMM showed no significant difference in the incidence of LOR compared to anti- TNF agent monotherapy (hazard ratio [HR], 1.64; 95% confidence interval [CI], 0.786 to 3.148; p = 0.182). Female sex was significantly associated with the development of LOR to anti-TNF (HR, 3.032; 95% CI, 1.467 to 6.268; p = 0.003). Conclusions: Anti-TNF and IMM combination therapy did not prove efficacious in preventing the development of LOR in IBD patients. Female sex was associated with the development of LOR to anti-TNF; further studies are required to confirm these results.
Abstract
Background/Aims: Combination therapy with immunomodulators (IMMs) was proposed as a strategy to prevent the development of loss of response (LOR) to anti- tumor necrosis factor (TNF) for patients with inflammatory bowel disease (IBD). However, the effect is unclear in patients already exposed to IMMs. The aim of this study was to evaluate whether combination therapy with IMMs is superior to monotherapy for prevention of LOR to anti-TNF. Methods: This was a retrospective study of patients in Seoul National University Bundang Hospital with IBD between January 2009 and October 2018. LOR was defined as clinical deterioration after maintenance of anti-TNF for at least 6 months. We investigated the difference in incidence of LOR to anti-TNF between the monotherapy and combination groups. We additionally assessed factors affecting LOR development to anti-TNF. Results: A total of 116 patients with IBD were included in this study (monotherapy 61 patients; combination 55 patients). Overall, LOR to anti-TNF occurred in 31 patients during the follow-up period. The combination of an anti-TNF agent and IMM showed no significant difference in the incidence of LOR compared to anti- TNF agent monotherapy (hazard ratio [HR], 1.64; 95% confidence interval [CI], 0.786 to 3.148; p = 0.182). Female sex was significantly associated with the development of LOR to anti-TNF (HR, 3.032; 95% CI, 1.467 to 6.268; p = 0.003). Conclusions: Anti-TNF and IMM combination therapy did not prove efficacious in preventing the development of LOR in IBD patients. Female sex was associated with the development of LOR to anti-TNF; further studies are required to confirm these results.
참고문헌 (15)
- Neurath MF, "Current and emerging therapeutic targets for IBD", Nat Rev Gastroenterol Hepatol, 14, pp.269~278 (2017)
- Roda G, "Loss of response to anti-TNFs : definition, epidemiology, and management", Clin Transl Gastroenterol, 7, pp.e135~ (2016)
- Ben-Horin S, "Review article : loss of response to anti-TNF treatments in Crohn’s disease", Aliment Pharmacol Ther, 33, pp.987~995 (2011)
- Colombel JF, "Infliximab, azathioprine, or combination therapy for Crohn’s disease", N Engl J Med, 362, pp.1383~1395 (2010)
- Panaccione R, "Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis", Gastroenterology, 146, pp.392~400 (2014)
- Jones JL, "Effects of concomitant immunomodulator therapy on efficacy and safety of anti-tumor necrosis factor therapy for Crohn’s disease : a meta-analysis of placebo-controlled trials", Clin Gastroenterol Hepatol, 13, pp.2233~2240 (2015)
- Billiet T, "Prognostic factors for long-term infliximab treatment in Crohn’s disease patients : a 20-year single centre experience", Aliment Pharmacol Ther, 44, pp.673~683 (2016)
- Varma P, "Immunomodulator use does not prevent first loss of response to anti-tumour necrosis factor alpha therapy in inflammatory bowel disease : long-term outcomes in a real-world cohort", Intern Med J, 49, pp.753~760 (2019)
- Satsangi J, "The Montreal classification of inflammatory bowel disease : controversies, consensus, and implications", Gut, 55, pp.749~753 (2006)
- Hommes DW, "Infliximab treatment for Crohn’s disease : one-year experience in a Dutch academic hospital", Inflamm Bowel Dis, 8, pp.81~86 (2002)
- Teshima CW, "Long-term response rates to infliximab therapy for Crohn’s disease in an outpatient cohort", Can J Gastroenterol, 23, pp.348~352 (2009)
- Qiu Y, "Systematic review with meta-analysis : loss of response and requirement of anti-TNFα dose intensification in Crohn’s disease", J Gastroenterol, 52, pp.535~554 (2017)
- Dumitrescu G, "The outcome of infliximab dose doubling in 157 patients with ulcerative colitis after loss of response to infliximab", Aliment Pharmacol Ther, 42, pp.1192~1199 (2015)
- van der Have M, "Non-adherence to anti-TNF therapy is associated with illness perceptions and clinical outcomes in outpatients with inflammatory bowel disease : results from a prospective multicentre study", J Crohns Colitis, 10, pp.549~555 (2016)
- Schultheiss JPD, "Earlier discontinuation of TNF-α inhibitor therapy in female patients with inflammatory bowel disease is related to a greater risk of side effects", Aliment Pharmacol Ther, 50, pp.386~396 (2019)